VASH2 and breast carcinoma: Recently, VASH2 has been demonstrated to be involved in the malignant behavior of a number of malignancies, including hepatic cancer [5, 6], ovarian cancer [7, 8], endometrial cancer [9], gastrointestinal cancers [10], breast cancer [11], and pancreatic cancer [12].